EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ensysce Advances Overdose Protection Platform in Clinical Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals for Nafamostat Hydrochloride

    Menu

    Nafamostat Hydrochloride

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Quotient Sciences

              Contact Supplier
              • Deals
              Virtual BoothQuotient Sciences- Molecule to Cure. Fast.
              Contact Supplier Contact Supplier
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ensysce Advances Overdose Protection Platform in Clinical Development

              Details:

              The collaboration aims to examine and evaluate the full commercial dose range of the PF614-MPAR drug product, the combination of PF614 with the trypsin inhibitor nafamostat, to treat chronic pain.

              Lead Product(s): Oxycodone Prodrug,Nafamostat Hydrochloride

              Therapeutic Area: Neurology Product Name: PF614-MPAR

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Ensysce Biosciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 20, 2024

              Quotient

              ChemOutsourcing

              Attending

              envelop Contact Supplier

              With Fermion, start the journey of your innovative API.
              Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
              Post Enquiry
              POST ENQUIRY